Dec 30, 2022

Neuroscientists developed a blood-based biomarker for Alzheimer’s diagnosis

Posted by in categories: biotech/medical, neuroscience

A significant step toward improved accessibility.

Neuroscientists from the University of Pittsburgh School of Medicine developed a new test to identify a sign of Alzheimer’s disease neurodegeneration in a blood sample, according to a press release.

“At present, diagnosing Alzheimer’s disease requires neuroimaging,” said senior author Thomas Karikari, Ph.D., assistant professor of psychiatry at Pitt.

Artur Plawgo/iStock.

Called “brain-derived tau” (BD-tau), the biomarker is specific to neurodegenerations related to Alzheimer’s disease, and it reportedly outperforms currently used blood diagnostic tests.

Comments are closed.